Minjee Kim
University of Minnesota
PharmacokineticsMagnetic resonance imagingVascular endothelial growth factor ATransporterKnockout mouseKinaseChemistryEffluxIn vitroIn vivoMdm2GlioblastomaMelanomaErlotinibBlood–brain barrierBrain tumorEpidermal growth factor receptorDrug deliveryDrugPonatinibFree fractionTumor growthCancer researchAbcg2MAPK/ERK pathwayKinesinBioinformaticsMedicineProtein kinase APharmacologyDistribution (pharmacology)
22Publications
6H-index
102Citations
Publications 24
Newest
#1Jessica I. Griffith (UMN: University of Minnesota)H-Index: 2
#2Minjee Kim (UMN: University of Minnesota)H-Index: 6
Last. William F. Elmquist (UMN: University of Minnesota)H-Index: 53
view all 10 authors...
Novel combinations of specific opioid agonists like loperamide and oxymorphindole targeting the µ- and δ-opioid receptors, respectively, have shown increased potency with minimized opioid-associated risks. However, whether their interaction is pharmacokinetic or pharmacodynamic in nature has not been determined. This study quantitatively determined whether these drugs have a pharmacokinetic interaction that alters systemic disposition or CNS distribution. We performed IV and oral in vivo pharmac...
Source
#1Surabhi Talele (UMN: University of Minnesota)H-Index: 1
#2Wenjuan Zhang (UMN: University of Minnesota)H-Index: 7
Last. William F. Elmquist (UMN: University of Minnesota)H-Index: 53
view all 10 authors...
The effective treatment of brain tumors is a considerable challenge in part due to the presence of the blood-brain barrier (BBB) that limits drug delivery. Glioblastoma (GBM) is an aggressive and infiltrative primary brain tumor with an extremely poor prognosis following standard of care therapy with surgery, radiation therapy (RT), and chemotherapy. DNA damage response (DDR) pathways play a critical role in DNA repair in cancer cells, and inhibition of these pathways can potentially augment RT ...
Source
#1Bianca Maria Marin (Mayo Clinic)H-Index: 1
#2Kendra A Porath (Mayo Clinic)H-Index: 1
Last. Jann N. Sarkaria (Mayo Clinic)H-Index: 70
view all 30 authors...
BACKGROUND Antibody drug conjugates (ADCs) targeting the epidermal growth factor receptor (EGFR), such as depatuxizumab mafodotin (Depatux-M), is a promising therapeutic strategy for glioblastoma (GBM) but recent clinical trials did not demonstrate a survival benefit. Understanding the mechanisms of failure for this promising strategy is critically important. METHODS PDX models were employed to study efficacy of systemic vs intracranial delivery of Depatux-M. Immunofluorescence and MALDI-MSI wer...
Source
#1Rachael A. Vaubel (Mayo Clinic)H-Index: 9
#2Ann C. Mladek (Mayo Clinic)H-Index: 21
Last. Jann N. Sarkaria (Mayo Clinic)H-Index: 70
view all 13 authors...
Source
#1Gautham Gampa (UMN: University of Minnesota)H-Index: 7
#2Rajappa S. Kenchappa (Mayo Clinic)H-Index: 21
Last. William F. Elmquist (UMN: University of Minnesota)H-Index: 53
view all 12 authors...
Glioblastoma, the most lethal primary brain cancer, is extremely proliferative and invasive. Tumor cells at tumor/brain-interface often exist behind a functionally intact blood-brain barrier (BBB), and so are shielded from exposure to therapeutic drug concentrations. An ideal glioblastoma treatment needs to engage targets that drive proliferation as well as invasion, with brain penetrant therapies. One such target is the mitotic kinesin KIF11, which can be inhibited with ispinesib, a potent mole...
Source
#1Gautham Gampa (UMN: University of Minnesota)H-Index: 7
#2Surabhi Talele (UMN: University of Minnesota)H-Index: 1
Last. William F. Elmquist (UMN: University of Minnesota)H-Index: 53
view all 6 authors...
Abstract Brain tumors are difficult to treat, in part, due to lack of adequate drug delivery across the blood–brain barrier (BBB). Although the BBB is compromised to some degree in brain tumors, it is not uniformly disrupted and some tumor locations have a relatively intact BBB. The presence of transporters (efflux) at the BBB limits the brain distribution of therapeutics intended for the treatment of CNS disorders. The differences in clearance processes, arising due to differences in the transp...
Source
#1Ann C. Mladek (Mayo Clinic)H-Index: 21
#2Shiv K. Gupta (Mayo Clinic)H-Index: 43
Last. Jann N. Sarkaria (Mayo Clinic)H-Index: 70
view all 11 authors...
Cell survival following radiation therapy (RT) is critically modulated by multiple DNA damage response pathways including the p53 tumor suppressor, which promotes cell cycle arrest and/or apoptosis in the face of DNA damage. Murine Double Minute 2 (MDM2) targets p53 for degradation and suppresses its functions. The MDM2 locus is amplified in approximately 14% of glioblastoma (GBM) tumors and is a promising target for individualized therapy. In these studies, we tested the MDM2 small molecule inh...
Source
#1Gautham Gampa (UMN: University of Minnesota)H-Index: 7
#2Rajappa S. Kenchappa (Mayo Clinic)H-Index: 21
Last. William F. Elmquist (UMN: University of Minnesota)H-Index: 53
view all 8 authors...
Source
#1Pamela R. Jackson (Mayo Clinic)H-Index: 9
#2Minjee Kim (UMN: University of Minnesota)H-Index: 6
Last. Kristin R. Swanson (Mayo Clinic)H-Index: 48
view all 12 authors...
Source
#1Surabhi Talele (UMN: University of Minnesota)H-Index: 1
#2Afroz S. Mohammad (UMN: University of Minnesota)H-Index: 12
Last. William F. Elmquist (UMN: University of Minnesota)H-Index: 53
view all 7 authors...
Glioblastoma (GBM) is an aggressive and infiltrative primary brain tumor with a median survival of 14.6 months following the current treatment strategy of radiation and chemotherapy. Therefore, there is a need to develop strategies to enhance the efficacy of chemo-radiation treatments for GBM. DNA damage response signaling pathways play a critical role in DNA repair and cell survival following radiation therapy and the inhibition of these pathways could augment the cytotoxicity associated with r...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.